InnerworldM to Mergers and Acquisitions (M&A)English · 7 days agoGSK's record $10.6B deal for US company Nuvalent will accelerate British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZeneca and Rochewww.reuters.comexternal-linkmessage-square0linkfedilinkarrow-up11arrow-down10
arrow-up11arrow-down1external-linkGSK's record $10.6B deal for US company Nuvalent will accelerate British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZeneca and Rochewww.reuters.comInnerworldM to Mergers and Acquisitions (M&A)English · 7 days agomessage-square0linkfedilink
